drugset / Trial / NCT03012672

Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm

NCT03012672

RandomizedParallel-groupOpen-labelTreatment

Summary

This randomized pilot trial studies how well higher or lower dose cladribine, cytarabine, and mitoxantrone work in treating medically less fit patients with newly diagnosed acute myeloid leukemia or myeloid neoplasm. Drugs used in chemotherapy, such as cladribine, cytarabine, and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cladribine, cytarabine, and mitoxantrone at higher or lower dose may work better in treating patients with newly diagnosed acute myeloid leukemia.

Timeline

Start
2016-12-30
Primary completion
2020-12-10
Completion
2021-02-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Cladribine Small molecule Intravenous
Subject Cytarabine Small molecule Intravenous
Subject Mitoxantrone Small molecule Intravenous
Background Granulocyte colony-stimulating factor Protein / enzyme biologic Subcutaneous